PDF(Pubmed)
Abstract：
UNASSIGNED: Few studies have reported the integrated characteristics of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after long-term antiviral therapy. This study aimed to investigate the HBV integration features in HBV-HCC patients who had undergone long-term antiviral therapy, evaluate their impact on clinical indicators, and analyze the potential mechanisms involved.
UNASSIGNED: We utilized genome-wide association study (GWAS) to analyze liver cancer tissues and detect the presence of HBV integration. Seventeen patients with HBV integration were included in the integration (Int) group, while the remaining five patients were included in the non-integration (N-int) group. Clinical indicators were regularly monitored and compared between the two groups. The characteristics of HBV integration patterns were analyzed, and differences between the groups were explored at the chromosome and genomic levels.
UNASSIGNED: After long-term antiviral therapy, although the frequency of HBV integration in HBV-HCC was reduced, residual HBV integration still accelerated the development of HCC. It affected the diagnosis, treatment, and prognosis of patients. HBV integration events led to changes in chromosome structure, which were closely related to HCC. Novel fusion genes were detected at a high frequency and had the potential to be specific detection sites for HBV-HCC.
UNASSIGNED: HBV integration events are synergistically involved in the human genome and HBV, which can lead to chromosome structural instability, gene rearrangement events closely related to HCC production, and the formation of new specific fusion genes.
UNASSIGNED: We utilized genome-wide association study (GWAS) to analyze liver cancer tissues and detect the presence of HBV integration. Seventeen patients with HBV integration were included in the integration (Int) group, while the remaining five patients were included in the non-integration (N-int) group. Clinical indicators were regularly monitored and compared between the two groups. The characteristics of HBV integration patterns were analyzed, and differences between the groups were explored at the chromosome and genomic levels.
UNASSIGNED: After long-term antiviral therapy, although the frequency of HBV integration in HBV-HCC was reduced, residual HBV integration still accelerated the development of HCC. It affected the diagnosis, treatment, and prognosis of patients. HBV integration events led to changes in chromosome structure, which were closely related to HCC. Novel fusion genes were detected at a high frequency and had the potential to be specific detection sites for HBV-HCC.
UNASSIGNED: HBV integration events are synergistically involved in the human genome and HBV, which can lead to chromosome structural instability, gene rearrangement events closely related to HCC production, and the formation of new specific fusion genes.
摘要：
■很少有研究报道长期抗病毒治疗后乙型肝炎病毒（HBV）相关肝细胞癌（HCC）的综合特征。本研究旨在探讨HBV整合特征在HBV-HCC患者谁经历了长期抗病毒治疗，评估它们对临床指标的影响，并分析其中的潜在机制。
■我们利用全基因组关联研究（GWAS）来分析肝癌组织并检测HBV整合的存在。17例HBV整合患者纳入整合（Int）组，而其余5例患者被纳入非整合（N-int）组。定期监测并比较两组患者的临床指标。分析HBV整合模式的特点,并在染色体和基因组水平上探索了组间的差异。
■长期抗病毒治疗后，虽然HBV整合在HBV-HCC的频率降低，残余HBV整合仍加速HCC的发展。它影响了诊断，治疗,和患者的预后。HBV整合事件导致染色体结构的变化，与HCC密切相关。新的融合基因检测频率高，有可能成为HBV-HCC的特异性检测位点。
■HBV整合事件协同参与人类基因组和HBV，这会导致染色体结构不稳定，与肝癌产生密切相关的基因重排事件，并形成新的特定融合基因。
■我们利用全基因组关联研究（GWAS）来分析肝癌组织并检测HBV整合的存在。17例HBV整合患者纳入整合（Int）组，而其余5例患者被纳入非整合（N-int）组。定期监测并比较两组患者的临床指标。分析HBV整合模式的特点,并在染色体和基因组水平上探索了组间的差异。
■长期抗病毒治疗后，虽然HBV整合在HBV-HCC的频率降低，残余HBV整合仍加速HCC的发展。它影响了诊断，治疗,和患者的预后。HBV整合事件导致染色体结构的变化，与HCC密切相关。新的融合基因检测频率高，有可能成为HBV-HCC的特异性检测位点。
■HBV整合事件协同参与人类基因组和HBV，这会导致染色体结构不稳定，与肝癌产生密切相关的基因重排事件，并形成新的特定融合基因。
